<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203433</url>
  </required_header>
  <id_info>
    <org_study_id>DLX105-DMP-201</org_study_id>
    <nct_id>NCT04203433</nct_id>
  </id_info>
  <brief_title>A Study of DLX105-DMP in Patients With Plaque Psoriasis</brief_title>
  <official_title>A Pilot, Open-Label, Two-Part Study in Subjects With Mild-to-Moderate Plaque Psoriasis to Investigate the Dosing Feasibility, Safety, Tolerability, and Preliminary Efficacy of DLX105-DMP Administered to a Target Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DelArrivo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DelArrivo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pilot, Open-Label, Two-Part Study in Subjects with Mild to Moderate Plaque Psoriasis to
      Investigate the Dosing Feasibility, Safety, and Local Tolerability of a Single Dose of
      DLX105-DMP Administered to a Target Lesion and the Safety, Local Tolerability, and
      Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target
      Lesion
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Two-part study: In part 1, subjects will receive a single dose of DLX105-DMP. In part 2, subjects will receive a 4-week regimen of DLX105-DMP.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Tolerability Sensations</measure>
    <time_frame>Up to 4 Weeks</time_frame>
    <description>4-point likert scale: 0 = none, 1 = mild, 2 = moderate, or 3 = severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Site Application Assessment</measure>
    <time_frame>Up to 4 Weeks</time_frame>
    <description>Investigator Assessment of Site Application Area using a 5-point scale: 0 = no visible reaction to 5 = severe erythema with induration/vesicles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1 through End of Study (Up to 4 Weeks after Last Dose)</time_frame>
    <description>Treatment Emergent Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Investigator Global Assessment (IGA)</measure>
    <time_frame>Day 1 through End of Study (Up to 4 Weeks after Last Dose) - Study Part 2 only</time_frame>
    <description>Local Investigator Global Assessment of Target Lesion, using a 5-point scale: 0 = clear to 5 = severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Psoriasis Area Severity Index (Local PASI)</measure>
    <time_frame>Day 1 through End of Study (Up to 4 Weeks after Last Dose) - Study Part 2 only</time_frame>
    <description>Local Psoriasis Area Severity Index Total Score for the Target Lesion, total score of 0 to 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters</measure>
    <time_frame>Day 1, Day 15, and Day 25 (Study Part 2 Only)</time_frame>
    <description>DLX105 concentrations in samples collected over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Testing</measure>
    <time_frame>Up to 4 Weeks after Last Dose (Study Part 2 Only)</time_frame>
    <description>Presence of antidrug antibodies and drug neutralizing antibodies in samples collected over time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>DLX105-DMP Single-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-Dose of 1mg DLX105-DMP applied to a target lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DLX105-DMP Multi-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Weeks of 1mg DLX105-DMP applied to a target lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLX105-DMP</intervention_name>
    <description>1mg applied to target lesion</description>
    <arm_group_label>DLX105-DMP Multi-Dose</arm_group_label>
    <arm_group_label>DLX105-DMP Single-Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed and dated informed consent.

          -  Subjects aged 18-75 years.

          -  Male subject, or if female, must be surgically sterile, post-menopausal, or using
             acceptable birth control.

          -  Stable chronic mild-to-moderate plaque-type psoriasis.

        Key Exclusion Criteria:

          -  Forms of psoriasis other than chronic plaque-type only (e.g., pustular, erythrodermic
             and guttate psoriasis, palmar, plantar or nail disease) at Screening.

          -  Drug-induced psoriasis (i.e., new onset or exacerbation from beta-blockers, calcium
             channel inhibitors or lithium) within 3 months prior to Day 1.

          -  Ongoing use of psoriasis treatments or inadequate duration of washout prior to Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Manager</last_name>
    <phone>919-460-9500</phone>
    <phone_ext>2003</phone_ext>
    <email>Kabernathy@QuatroBio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>DelArrivo Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no current plan to make individual participant data available to other researchers; however, if study results are published, then de-identified IPD may be made available in connection with the publication.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

